These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23962533)

  • 21. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pfizer’s men B vaccine shows promise in phase 2.
    Hum Vaccin Immunother; 2012 Aug; 8(8):1016-7. PubMed ID: 23359878
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
    Oviedo-Orta E; Ahmed S; Rappuoli R; Black S
    Vaccine; 2015 Jul; 33(31):3628-35. PubMed ID: 26093201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.
    McNamara LA; Mbaeyi S
    Lancet Infect Dis; 2021 May; 21(5):586-587. PubMed ID: 33428869
    [No Abstract]   [Full Text] [Related]  

  • 30. [Health Technology Assessment of meningococcal B vaccine (Trumenba
    Boccalini S; Bechini A; Sartor G; Paolini D; Innocenti M; Bonanni P; Panatto D; Lai PL; Zangrillo F; Marchini F; Lecini E; Iovine M; Amicizia D; Landa P
    J Prev Med Hyg; 2019 Dec; 60(3 Suppl 2):E1-E94. PubMed ID: 32047867
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 32. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bexsero--a second serogroup B meningococcal vaccine.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):158-9. PubMed ID: 26583605
    [No Abstract]   [Full Text] [Related]  

  • 35. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 36. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 37. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urticarial vasculitis after meningococcal serogroup B vaccine in a 6-year-old girl.
    Velasco-Tamariz V; Prieto-Barrios M; Tous-Romero F; Palencia-Pérez SI; Postigo-Llorente C
    Pediatr Dermatol; 2018 Jan; 35(1):e64-e65. PubMed ID: 29164681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Authors' response: Meningococcal vaccine antigen diversity in global databases.
    Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC
    Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935
    [No Abstract]   [Full Text] [Related]  

  • 40. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.
    Rose WE
    J Am Pharm Assoc (2003); 2014; 54(2):198-201. PubMed ID: 24632933
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.